Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does genetic screening increase detection of familial medullary thyroid cancer in apparently sporadic cases?

Nature Clinical Practice Endocrinology & Metabolism volume 4, pages 132–133 (2008)Cite this article

boxed-text Elisei R et al. (2007) RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab [doi:10.1210/jc.2007-1005]

All patients with apparently sporadic or familial MTC should have comprehensive screening for mutations in the RET proto-oncogene; the timing of prophylactic surgery and subsequent management are both influenced by the specific mutation

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cote GJ and Gagel RF (2003) Lessons learned from the management of a rare genetic cancer. N Engl J Med 349: 1566–1568

    Article  CAS  PubMed  Google Scholar 

  2. De Groot JW et al. (2006) RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 27: 535–560

    Article  CAS  PubMed  Google Scholar 

  3. Wohllk N et al. (1996) Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81: 3740–3745

    CAS  PubMed  Google Scholar 

  4. Learoyd DL and Robinson BG (2005) Do all patients with RET mutations associated with multiple endocrine neoplasia type 2 require surgery? Nat Clin Pract Endocrinol Metab 1: 60–61

    Article  CAS  PubMed  Google Scholar 

  5. Carlomagno F et al. (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity efficiently blocks oncogenic RET kinases. Cancer Res 62: 7284–7290

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. DL Learoyd is a Senior Lecturer in the Department of Medicine and BG Robinson is the Dean of the Faculty of Medicine, University of Sydney, Australia.,

    Diana L Learoyd & Bruce G Robinson

Authors
  1. Diana L Learoyd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce G Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruce G Robinson.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Learoyd, D., Robinson, B. Does genetic screening increase detection of familial medullary thyroid cancer in apparently sporadic cases?. Nat Rev Endocrinol 4, 132–133 (2008). https://doi.org/10.1038/ncpendmet0722

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0722

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing